查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571645

肿瘤分析市场规模、份额、趋势分析报告：按方法、按技术、按应用、按地区、细分市场预测，2024-2030 年

Tumor Profiling Market Size, Share & Trends Analysis Report By Technique (Genomics, Proteomics), By Technology, By Application (Personalized Cancer Medicine, Oncological Diagnostics, Research), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

肿瘤分析市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球肿瘤分析市场规模预计将达到217.3亿美元，2024年至2030年复合年增长率为10.3%。

预计增加体学科学在癌症检测的应用研究将影响市场成长。

生物技术的进步使我们能够深入了解新陈代谢和基因表现。这些正在加速代谢体学和表观遗传学等先进技术在癌症筛检和检测中的应用。因此，随着下游应用的扩展，癌症肿瘤/分析（CTP）技术的需求预计将良好成长。

癌症肿瘤分析是一种潜在的方法，可以进一步研究它以检测癌症并识别肿瘤阶段、代谢和形态的变化。这对于常规诊断和治疗决策很有用。肿瘤分析对于根据疾病严重程度和个体基因组图谱开发针对特定个体的治疗方法具有重要意义。

NGS 和原位杂交等检测和测序技术的增强将有助于加快癌症肿瘤分析过程，预计将在未来几年获得显着的发展。这些高采用率是由于以最少的资源和更高的准确性获得结果的速度加快。

肿瘤分析市场的报告亮点

  • 个人化癌症医学预计将成为采用 CTP 的最有利的应用领域。
  • 由于从癌细胞的基因组、表观基因和代谢组学分析中获得的功能资讯的不同用途和相互依赖性，预计这些技术领域将相互协同发展，并在预测期内表现出良好的增长。
  • 由于主要经济体的各种发展以及新兴经济体领先企业的日益突出，预计亚太地区在未来十年将经历显着成长。
  • 主要企业包括 Illumina, Inc.、Qiagen NV、Neogenomics Laboratories Inc.、HTG Molecular Diagnostics, Inc.、Genomic Health Inc.、Caris Life Sciences Helomics Corporation、Nanostring Technologies、Oxford Gene Technology、Ribomed Biotechnologies, Inc.、nosPersonal Genome Diagtics 、GenomeDX、Guardant Health、基础医学等。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章肿瘤分析市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 肿瘤分析市场分析工具
    • 波特的分析
    • PESTEL分析

第四章肿瘤分析市场：方法估计与趋势分析

  • 细分仪表板
  • 肿瘤分析市场：方法变异分析，百万美元，2023 年和 2030 年
  • 基因组学
  • 蛋白质体学
  • 代谢体学
  • 表观遗传学

第五章肿瘤谱分析市场：技术评估与趋势分析

  • 细分仪表板
  • 肿瘤分析市场：技术变迁分析，百万美元，2023-2030
  • 定序技术
  • 原位杂交
  • 免疫组织化学
  • 定量PCR
  • 微阵列

第六章 肿瘤分析市场：应用估算与趋势分析

  • 细分仪表板
  • 肿瘤分析市场：应用变化分析，百万美元，2023-2030
  • 个人化癌症治疗
  • 肿瘤诊断
  • 研究
    • 癌症研究
    • 生物标记发现

第七章肿瘤分析市场：区域估计与趋势分析

  • 2023 年和 2030 年按地区分類的肿瘤分析市场占有率，百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 最新趋势与影响分析：主要市场参与企业
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Illumina, Inc.
    • QIAGEN
    • Genomic Health
    • Neogenomics Inc.
    • Life Sciences
    • Oxford Gene Technology
    • Bruker Spatial Biology, Inc.
    • Ribomed Biotechnologies Inc.
    • GenomeDX
    • Guardant Health
    • FOUNDATION MEDICINE, INC.
简介目录
Product Code: GVR-2-68038-625-7

Tumor Profiling Market Growth & Trends:

The global tumor profiling market size is expected to reach USD 21.73 billion by 2030, expanding at a CAGR of 10.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising research in the application of omics sciences in cancer detection is anticipated to influence market growth.

Technological advances in biotechnology have allowed for deeper insights into metabolism and gene expression. These have accelerated the application of advanced techniques such as metabolomics and epigenetics in cancer screening and detection. Thus, demand for cancer tumor/profiling (CTP) techniques is anticipated to witness lucrative growth with the expansion of downstream applications.

Cancer tumor profiling is a potential procedure through which cancer can be detected and studied further to identify the stage, metabolism, and changes in morphology of the tumor. This aids in routine diagnostics as well as therapeutic decision-making. Tumor profiling has significant importance in developing therapies aimed at a specific individual, based on the severity of ailment and genomic build up of the individual.

Enhanced detection and sequencing techniques such as NGS and in-situ hybridization can help speed up the cancer tumor profiling process and are estimated to gain much traction over the coming years. Their high adoption is attributive to accelerated speed in gaining results with minimum resources and greater accuracy.

Tumor Profiling Market Report Highlights:

  • Personalized cancer medicine is expected to be the most lucrative application segment for CTP adoption.
  • Owing to difference in usage of and interdependency of functional information from genomic, epigenomic, and metabolomic analysis of cancer cells, it can be expected that these technology segments will grow in tandem with each other and exhibit lucrative growth over the forecast years
  • Asia Pacific is projected to witness substantial growth over the next decade owing to various developments across major economies, with increased focus of dominant players in emerging economies as well
  • Key players include Illumina, Inc.; Qiagen N.V.; Neogenomics Laboratories Inc.; HTG Molecular Diagnostics, Inc.; Genomic Health Inc.; Caris Life Sciences Helomics Corporation; Nanostring Technologies; Oxford Gene Technology; Ribomed Biotechnologies, Inc.; Personal Genome Diagnostics; GenomeDX; Guardant Health; and Foundation Medicine.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Tumor Profiling Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Tumor Profiling Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Tumor Profiling Market: Technique Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Tumor Profiling Market: Technique Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Genomics
    • 4.3.1. Genomics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Proteomics
    • 4.4.1. Proteomics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Metabolomics
    • 4.5.1. Metabolomics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Epigenetics
    • 4.6.1. Epigenetics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Tumor Profiling Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Tumor Profiling Market: Technology Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Sequencing Techniques
    • 5.3.1. Sequencing Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. NGS
      • 5.3.2.1. NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Sanger Sequencing
      • 5.3.3.1. Sanger Sequencing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. Pyro Sequencing
      • 5.3.4.1. Pyro Sequencing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. In Situ Hybridization
    • 5.4.1. In Situ Hybridization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Immunohistochemistry
    • 5.5.1. Immunohistochemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. qPCR
    • 5.6.1. qPCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Microarray
    • 5.7.1. Microarray Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Tumor Profiling Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Tumor Profiling Market: Application Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Personalized Cancer Medicine
    • 6.3.1. Personalized Cancer Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Oncological Diagnostics
    • 6.4.1. Oncological Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Research
    • 6.5.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Cancer Research
      • 6.5.2.1. Cancer Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Biomarker Discovery
      • 6.5.3.1. Biomarker Discovery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Tumor Profiling Market: Regional Estimates & Trend Analysis

  • 7.1. Tumor Profiling Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Illumina, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. QIAGEN
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Genomic Health
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Neogenomics Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Life Sciences
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Oxford Gene Technology
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bruker Spatial Biology, Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Ribomed Biotechnologies Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. GenomeDX
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Guardant Health
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. FOUNDATION MEDICINE, INC.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives